ARGOS THERAPEUTICS INC (ARGS) financial statements (2020 and earlier)

Company profile

Business Address 4233 TECHNOLOGY DR
DURHAM, NC 27704
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments81217159911
Cash and cash equivalents81217159911
Restricted cash and investments    112
Receivables0000000
Assets held-for-sale, not part of disposal group   1101010
Other undisclosed current assets1211111
Total current assets:9141917222226
Noncurrent Assets
Property, plant and equipment2334444
Other noncurrent assets0000000
Total noncurrent assets:2334444
TOTAL ASSETS:11172221262630
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3342789
Accounts payable0011113
Accrued liabilities3331676
Debt5555000
Restructuring reserve    002
Other undisclosed current liabilities2222265
Total current liabilities:991110101417
Noncurrent Liabilities
Long-term debt and lease obligation   121676
Long-term debt, excluding current maturities   121676
Liabilities, other than long-term debt91096671
Contract with customer, liability232
Due to related parties776666 
Derivative instruments and hedges, liabilities  00011
Total noncurrent liabilities:91091922137
Total liabilities:18192028322824
Stockholders' equity
Stockholders' equity attributable to parent(13)(8)(3)(9)(17)(21)(14)
Common stock0000000
Additional paid in capital374373372363354344342
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(386)(381)(375)(373)(371)(365)(356)
Total stockholders' equity:(13)(8)(3)(9)(17)(21)(14)
Other undisclosed liabilities and equity5662111919
TOTAL LIABILITIES AND EQUITY:11172221262630

Income statement (P&L) ($ in millions)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
Gross profit:1062000
Operating expenses(6)(6)(8)(4)(8)(8)(44)
Operating loss:(5)(6)(2)(2)(8)(8)(44)
Nonoperating income (expense)0(0)(0)02(0)0
Investment income, nonoperating0000000
Other nonoperating income (expense)(0)0(0)(0)0 (0)
Interest and debt expense0(0)(0)12(0)0
Net loss:(5)(7)(2)(1)(5)(9)(44)
Other undisclosed net income (loss) attributable to parent(0)00(1)(2)020
Net loss available to common stockholders, diluted:(5)(6)(2)(2)(6)(9)(24)

Comprehensive Income ($ in millions)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
Net loss:(5)(7)(2)(1)(5)(9)(44)
Other undisclosed comprehensive income (loss)(0)00(1)(2)020
Comprehensive loss, net of tax, attributable to parent:(5)(6)(2)(2)(6)(9)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: